
|Articles|January 19, 2012
Dr. Adil Daud Discusses Zelboraf and Yervoy for the Treatment of Metastatic Melanoma
Advertisement
Dr. Adil Daud, Clinical Professor of Medicine and Co-Director of the Melanoma Program, UCSF, discusses cost and the payer/provider relationship around metastatic melanoma medications.
vemurafenib (Brand name:
Dr. Daud discusses the use of Zelboraf) and ipilimumab (Brand name: Yervoy), the FDA-approved medications used in the treatment of metastatic melanoma. The medications are expensive, but Dr. Daud shares there have been little issue covering these specific drugs since they are so effective. Dr. Daud hopes that these are only the first class of this drug pathway extending life expectancy, as he hopes they can eventually bring metastatic melanoma to a chronic disease state and not a death sentence.
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Medicaid MFN Pricing Could Save $8.6 Billion
2
Active US Drug Shortages Rise for Third Straight Quarter
3
FAQs: FDA Lawsuit Challenges E-Cigarette Enforcement Policy, PMTA Guidance
4
Prior Cancer History Predicts Second Cancers in Polycythemia Vera, Essential Thrombocythemia
5




